<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cerebral amyloid angiopathy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cerebral amyloid angiopathy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cerebral amyloid angiopathy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven M Greenberg, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott E Kasner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral amyloid angiopathy (CAA) is characterized by amyloid beta-peptide deposits within small- to medium-sized blood vessels of the brain and leptomeninges. CAA is an important cause of lobar intracerebral hemorrhage in older adults [
         <a href="#rid1">
          1,2
         </a>
         ]. In addition to intracerebral hemorrhage, CAA may present with transient neurological symptoms, an inflammatory encephalopathy, as a contributor to cognitive impairment, or with incidental microbleeds or hemosiderosis on magnetic resonance imaging (MRI).
        </p>
        <p>
         The clinical features, diagnosis, and management of CAA is discussed here. Alzheimer disease, which is also characterized by abnormal amyloid beta-peptide deposits in the brain, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16575.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of Alzheimer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">
          "Clinical features and diagnosis of Alzheimer disease"
         </a>
         .)
        </p>
        <p>
         Other causes of intracerebral hemorrhage are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128433.html" rel="external">
          "Superficial siderosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of CAA is strongly age dependent. By autopsy, CAA can be identified by the replacement of at least some cerebral blood vessel walls with amyloid beta-peptide. In one series of 784 autopsy cases, the prevalence of CAA ranged from 2.3 percent for patients between the ages of 65 and 74, 8.0 percent for those age 75 to 84, and 12.1 percent in patients over the age of 85 [
         <a href="#rid3">
          3
         </a>
         ]. In an autopsy study of 1079 patients whose mean age at death was 89.7 years, the prevalence of moderate-to-severe CAA was 36 percent [
         <a href="#rid4">
          4
         </a>
         ]. CAA-related symptoms are uncommon at ages younger than 60 years but can occur in middle-aged or younger individuals either sporadically or due to rare genetic or iatrogenic causes [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p>
         The prevalence of CAA among older patients with dementia is higher than those without dementia. In a systematic review of population-based studies, nearly 60 percent of patients with dementia showed CAA pathology compared with less than 40 percent among those without dementia [
         <a href="#rid8">
          8
         </a>
         ]. Among patients with Alzheimer disease, more than 80 percent had pathologic evidence of CAA [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1975410857">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathology of CAA involves deposition of amyloid beta-peptide within the cerebral vasculature. Vascular amyloid deposits in CAA are biochemically similar to the material comprising senile plaques in Alzheimer disease [
         <a href="#rid1">
          1
         </a>
         ]. The primary constituent of each is amyloid beta-peptide, a 39 to 43 amino acid fragment of the amyloid precursor protein (APP).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development of CAA
         </strong>
         – The factors other than aging that initiate and promote amyloid beta-peptide deposition leading to CAA are not well understood. Genetic factors can cause CAA in an autosomal dominant manner and can increase the risk for sporadic CAA (see
         <a class="local">
          'Genetic susceptibilities'
         </a>
         below). Rarely, deposition of amyloid beta-peptide may occur with a neurosurgical procedure and/or exposure to cadaveric central nervous system tissue, and clinical manifestations of iatrogenic CAA may subsequently develop decades later [
         <a href="#rid7">
          7,10-12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development of hemorrhage
         </strong>
         – Vascular rupture and bleeding in CAA appear to be a multistep process involving the deposition of amyloid beta-peptide in the vascular wall and subsequent vascular changes such as concentric splitting of the vascular wall. The relationship between CAA and hypertension is debated. Although many patients with CAA-related hemorrhage are normotensive [
         <a href="#rid13">
          13-15
         </a>
         ], elevated blood pressure nonetheless appears to contribute to the risk of hemorrhage recurrence [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite shared pathologic features, the pathophysiology of CAA and Alzheimer disease appear distinct [
         <a href="#rid17">
          17
         </a>
         ]. There is no clinical overlap between amyloid beta CAA and the non-central nervous system systemic amyloidoses, such as primary (amyloid AL) and secondary (amyloid AA) amyloidosis.
        </p>
        <p class="headingAnchor" id="H905272184">
         <span class="h2">
          Genetic susceptibilities
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAA is sporadic in most patients. A small minority of patients have an identified monogenic cause [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amyloid precursor protein variant
         </strong>
         – Variant forms of the gene that encodes the APP are responsible for some cases of early-onset CAA that are inherited in an autosomal dominant pattern. While most of these variants are also associated with at least some of the neuropathologic features of Alzheimer disease, at least two APP variants (
         <em>
          Glu693Gln
         </em>
         and
         <em>
          Leu705Val
         </em>
         ) have been reported to cause autosomal-dominant CAA with minimal parenchymal amyloid plaques or neurofibrillary tangles [
         <a href="#rid18">
          18-20
         </a>
         ]. The Dutch-type
         <em>
          Glu693Gln
         </em>
         APP pathologic variant is associated with cerebral amyloid deposition with a more aggressive course than patients with sporadic CAA [
         <a href="#rid21">
          21
         </a>
         ]. The causative amino acid substitutions in these hereditary forms of CAA may increase the toxic effects of amyloid beta-peptide on the vessel wall [
         <a href="#rid22">
          22,23
         </a>
         ], decrease the peptide's susceptibility to proteolysis [
         <a href="#rid24">
          24
         </a>
         ], or impair its clearance from the central nervous system [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Apolipoprotein E
         </strong>
         – Patients carrying the apolipoprotein E (
         <em>
          APOE)
         </em>
         epsilon 2 (e2) or epsilon 4 (e4) alleles appear to be at greater risk for CAA-related hemorrhage than those with only the common
         <em>
          APOE
         </em>
         epsilon 3 (e3) allele [
         <a href="#rid26">
          26-30
         </a>
         ]. One systematic review found evidence for a dose-dependent association between
         <em>
          APOE
         </em>
         e4 and sporadic CAA [
         <a href="#rid31">
          31
         </a>
         ].
         <em>
          APOE
         </em>
         e4 also promotes deposition of amyloid beta-peptide in Alzheimer disease [
         <a href="#rid32">
          32
         </a>
         ] and following severe head injury [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          APOE
         </em>
         e2 or e4 alleles are present in approximately two-thirds of patients with CAA compared with only about one-quarter of older adult controls without evidence of CAA. These alleles are associated with an increased likelihood of having a CAA-related hemorrhage [
         <a href="#rid26">
          26,27
         </a>
         ], earlier age of disease onset (mean age of first hemorrhage 75 versus 82 years in patients who are not carriers of
         <em>
          APOE
         </em>
         e2 or e4), and a greater risk of hemorrhage recurrence (two-year cumulative recurrence rate of 28 percent in carriers of e2 or e4 versus 10 percent for the
         <em>
          APOE
         </em>
         e3/e3 genotype) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <em>
          APOE
         </em>
         e2 and e4 alleles act via separate mechanisms.
         <em>
          APOE
         </em>
         e4 increases amyloid beta-peptide deposition [
         <a href="#rid32">
          32
         </a>
         ].
         <em>
          APOE
         </em>
         e2 causes amyloid-laden vessels to undergo changes such as concentric wall splitting and necrosis that predispose to rupture [
         <a href="#rid27">
          27,35,36
         </a>
         ]. Patients with CAA who have both
         <em>
          APOE
         </em>
         e2 and e4 alleles appear to have a particularly early onset of disease and a high risk of early recurrence [
         <a href="#rid27">
          27,34
         </a>
         ]. Carriers of the
         <em>
          APOE
         </em>
         e2 allele also have larger intracerebral hemorrhage (ICH) volumes, increased mortality, and worse functional outcomes compared with noncarriers, while these associations are not seen for carriers of the
         <em>
          APOE
         </em>
         e4 allele [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data from a population-based, case-control study suggest that the risk of lobar ICH associated with
         <em>
          APOE
         </em>
         alleles may be modified by variation elsewhere in the
         <em>
          APOE
         </em>
         gene [
         <a href="#rid38">
          38
         </a>
         ]. Notably, overall
         <em>
          APOE
         </em>
         haplotype (combination of multiple alleles on one chromosome) was also independently associated with lobar ICH, suggesting the presence of regulatory variants that could influence the effect of
         <em>
          APOE
         </em>
         e2 or e4 on the risk of lobar ICH [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CR1 gene variant
         </strong>
         – A case-control genetic association study that included a prospective followup of 178 ICH survivors found that a variant within the
         <em>
          CR1
         </em>
         gene (rs6656401) influences the risk and recurrence of CAA-related ICH [
         <a href="#rid40">
          40
         </a>
         ]. In the same report, this genetic variant was also associated with the severity of vascular amyloid deposition on pathologic examination of 544 autopsy studies from two community-based clinical-pathological studies of aging.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2933686127">
         <span class="h1">
          ACUTE INTRACEREBRAL HEMORRHAGE
         </span>
         <span class="headingEndMark">
          —
         </span>
         − The most common clinical manifestation of CAA is acute lobar intracerebral hemorrhage (ICH)  (
         <a class="graphic graphic_diagnosticimage graphicRef50480" href="/z/d/graphic/50480.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. The term "lobar" refers to location in the cortex and subcortical white matter of a hemispheric lobe of the brain; this contrasts with the deep locations, such as putamen, thalamus, and pons, which are characteristic of hypertensive hemorrhage. The lobar location of the hemorrhages reflects the underlying distribution of the vascular amyloid deposits, which favor cortical vessels and largely spare white matter, deep gray matter, and the brainstem. Involvement of the blood vessels in the cerebellum and leptomeninges can also give rise to the less common clinical presentations of cerebellar or subarachnoid/subdural hemorrhage.
        </p>
        <p class="headingAnchor" id="H3531508290">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of CAA-related hemorrhage varies with the lesion size and brain region impacted. Lobar hemorrhages can cause hemiparesis from involvement of pyramidal motor neurons and tracts. A large lobar hemorrhage may cause depressed consciousness from direct involvement or secondary mass effect on reticular activating system networks. In comparison, smaller lobar or cerebellar hemorrhages may cause more limited focal deficits related to the underlying brain structure impacted. The clinical presentation of intracerebral hemorrhage is described in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         In rare cases, small cortical hemorrhages may irritate meningeal nociceptors to cause isolated headache. They may also infrequently be asymptomatic, found on imaging pursued for other indications [
         <a href="#rid42">
          42,43
         </a>
         ]. (See
         <a class="local">
          'Microbleeds'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H542951378">
         <span class="h2">
          Imaging features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imaging findings in acute hemorrhage can vary in size and location, but specific imaging patterns and associated findings are common in CAA-related hemorrhage.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lobar regions
         </strong>
         – CAA-related lobar hemorrhages preferentially arise in posterior lobar brain regions. Analysis of the spatial distribution of 321 intracerebral hemorrhages in 59 patients with CAA revealed that hemorrhages were significantly more likely to occur in the temporal and occipital than the frontal and parietal lobes (ratio of actual to expected hemorrhages 1.37, 1.43, 0.58, and 1.0, respectively) [
         <a href="#rid44">
          44
         </a>
         ]. The explanation for the posterior brain clustering of CAA hemorrhages is undetermined, but it may be related to as-yet unknown characteristics of posterior circulation vessels that influence amyloid beta-peptide elimination or to increased vulnerability of these brain regions to minor trauma [
         <a href="#rid44">
          44,45
         </a>
         ]. CAA-related lobar hemorrhages often extend beyond the brain tissue into the subarachnoid and subdural spaces and, less frequently, may rupture into ventricles [
         <a href="#rid46">
          46,47
         </a>
         ]. Extension of the hemorrhage into the subarachnoid space and the presence of elongated "finger-like" projections appear to be characteristic features of CAA-related lobar hemorrhages that may assist in diagnosis [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebellum
         </strong>
         – The cerebellum may contain variable amounts of vascular amyloid in individuals with CAA. The cerebellum is also a site of CAA-related hemorrhage, with predilection for the cerebellar cortex and vermis rather than the cerebellar nuclei and deep white matter [
         <a href="#rid49">
          49-51
         </a>
         ]. In a retrospective analysis of the brain MRIs from 112 patients with cerebellar ICH, those with superficial cerebellar ICH were likelier to meet diagnostic criteria for CAA (48 versus 9 percent) and to have other imaging features suggestive of CAA than patients with deep or mixed cerebellar ICH [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Convexity subarachnoid hemorrhage
         </strong>
         – Subarachnoid hemorrhage can also occur within the convexity of the cerebral hemispheres (cSAH) in patients with CAA due to amyloid deposition at the cortical surface. cSAH may occur along with acute ICH, located either adjacent to or remote from the ICH. In addition, patients may present with isolated cSAH and seizures or other focal symptoms due to dysfunction of underlying cortex. (See
         <a class="local">
          'Transient focal neurologic episodes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated chronic hemorrhagic findings
         </strong>
         – T2*-weighted gradient-echo or susceptibility-weighted brain MRI sequences obtained in patients with an acute lobar hemorrhage may also show chronic cerebral microbleeds (CMBs) and/or cortical superficial siderosis (cSS). CMBs are typically asymptomatic lesions and are found in the juxtacortical and cortical lobar regions with a predilection for temporal and occipital lobes. cSS represents cSAH in the chronic phase. The presence of cSS likely reflects severe CAA in the leptomeningeal vessels [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H741999397">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Differentiation of nontraumatic lobar ICH related to CAA from other causes depends upon the clinical and radiographic appearance. Other causes include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lobar extension of a hypertensive hemorrhage (see
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemorrhagic transformation of an ischemic stroke (see
         <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">
          "Neuroimaging of acute stroke"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemorrhagic venous infarction from cerebral venous thrombosis (see
         <a class="medical medical_review" href="/z/d/html/1103.html" rel="external">
          "Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemorrhage of arteriovenous malformation (AVM) (see
         <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">
          "Vascular malformations of the central nervous system"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemorrhagic tumor (see
         <a class="medical medical_review" href="/z/d/html/5180.html" rel="external">
          "Overview of the clinical features and diagnosis of brain tumors in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Clinical features that favor diagnoses other than CAA include younger age (many hemorrhages attributed to AVM occur before age 35 to 40 [
         <a href="#rid54">
          54
         </a>
         ]), prodromal symptoms (progressive headache may suggest cerebral venous thrombosis), or patient-level risk factors (eg, active metastatic cancer may suggest hemorrhagic tumor, high thromboembolic risk in a patient with atrial fibrillation not treated with anticoagulation may suggest hemorrhagic transformation of ischemic infarct).
        </p>
        <p>
         Imaging features may also help identify diagnoses other than CAA in patients with lobar hemorrhage  (
         <a class="graphic graphic_table graphicRef140108" href="/z/d/graphic/140108.html" rel="external">
          table 1
         </a>
         ). Brain MRI can help identify evidence of acute ischemia or enhancement associated with tumors. Corresponding computed tomographic (CT) angiography or MR angiographic studies can help identify the presence of an associated arterial or venous occlusion or AVM. This differential diagnosis and the evaluation to determine etiology is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Subsequent imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1306046273">
         <span class="h2">
          Diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of CAA should be suspected clinically in patients age 50 years or older with or without a clinical manifestation of CAA who have characteristic acute or chronic hemorrhagic findings and/or white matter features on brain MRI in the absence of an alternative cause.
        </p>
        <p>
         Definite CAA is only diagnosed postmortem. A full pathologic examination of the brain showing amyloid deposition with vasculopathy, evidence of brain hemorrhage, and absence of other diagnostic lesions confirms CAA [
         <a href="#rid55">
          55
         </a>
         ]. During life, the diagnosis of probable CAA can be made with clinical evaluation and MRI of the brain. Examination of a sample of brain tissue obtained by brain biopsy further supports the diagnosis but is infrequently performed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients, we use hemorrhagic imaging features on T2*-weighted MRI sequences and additional white matter markers to support the diagnosis of probable CAA. (See
         <a class="local">
          'Imaging-based diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For select patients in whom imaging features are equivocal or the cause of a clinical manifestation is uncertain, we use additional adjunctive testing. (See
         <a class="local">
          'Adjunctive diagnostic testing for some patients'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3252068486">
         <span class="h3">
          Imaging-based diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with suspected CAA should undergo brain MRI, including T2*-weighted sequences, which accentuate the signal dropout caused by iron-containing deposits left by old hemorrhages  (
         <a class="graphic graphic_diagnosticimage graphicRef81579" href="/z/d/graphic/81579.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid56">
          56
         </a>
         ]. Chronic lobar hemorrhages, cSS, and CMBs appear dark on such sequences. Inclusion of white matter features, including enlarged perivascular spaces in the centrum semiovale and multispot pattern subcortical hyperintensities on T2-weighted sequences in the MRI criteria for probable CAA, increased the diagnostic sensitivity in version 2.0 of the Boston criteria [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="local">
          'The Boston criteria for CAA'
         </a>
         below.)
        </p>
        <p>
         To support the diagnosis of probable CAA with MRI, we look for the presence of either of the following findings not attributable to another cause [
         <a href="#rid57">
          57
         </a>
         ] (see
         <a class="local">
          'Differential diagnosis'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two or more hemorrhagic lesions (ICH, CMB, cSAH, or cSS foci in any combination) in the lobar brain regions, entirely sparing regions typical of hypertensive hemorrhage (basal ganglia, thalamus, or pons)  (
         <a class="graphic graphic_diagnosticimage graphicRef132283" href="/z/d/graphic/132283.html" rel="external">
          image 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef132282" href="/z/d/graphic/132282.html" rel="external">
          image 4
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef121315" href="/z/d/graphic/121315.html" rel="external">
          image 5
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef130369" href="/z/d/graphic/130369.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid58">
          58-60
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One lobar hemorrhagic lesion and one white matter lesion, defined as either severe (ie, &gt;20 per hemisphere) dilated perivascular spaces in the centrum semiovale or multiple (ie, &gt;10) ovoid-shaped white matter hyperintensities on T2-weighted imaging in bilateral subcortical regions
        </p>
        <p>
        </p>
        <p>
         A single hemorrhagic lesion (eg, lobar hemorrhage, cSAH, cSS focus, or lobar CMB) or isolated white matter features create less diagnostic certainty but can be suggestive of the diagnosis (classified as "possible CAA").
        </p>
        <p class="headingAnchor" id="H834273461">
         <span class="h3">
          The Boston criteria for CAA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Boston criteria provide a framework for various levels of diagnostic certainty in patients with intracerebral hemorrhage with or without pathologic tissue analysis  (
         <a class="graphic graphic_table graphicRef139328" href="/z/d/graphic/139328.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Initial versions of the criteria included clinical, radiologic, and pathologic data to support the diagnosis of CAA [
         <a href="#rid55">
          55,59
         </a>
         ]. The Boston criteria version 2.0 for sporadic CAA update the modified Boston criteria to include expanded imaging findings (hemorrhagic and white matter features) with validation data across multiple time epochs, medical centers, and both hemorrhagic and nonhemorrhagic clinical presentations  (
         <a class="graphic graphic_table graphicRef139328" href="/z/d/graphic/139328.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Transient focal neurologic episodes'
         </a>
         below and
         <a class="local">
          'Cerebral amyloid angiopathy-related inflammation'
         </a>
         below and
         <a class="local">
          'Cognitive impairment'
         </a>
         below and
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         below.)
        </p>
        <p>
         In a retrospective, multicenter review of 341 patients who presented with clinical features consistent with CAA and had both MRI and brain tissue available for analysis, the inclusion of additional imaging findings to the Boston criteria version 2.0 produced a higher diagnostic accuracy for probable CAA than the previous modified Boston criteria (84.8 versus 79.8 percent) [
         <a href="#rid57">
          57
         </a>
         ]. The specificity was 95 percent for both sets of criteria.
        </p>
        <p class="headingAnchor" id="H913977058">
         <span class="h3">
          Adjunctive diagnostic testing for some patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         While not commonly performed for evaluation and diagnosis of most patients with typical symptoms and imaging findings, additional testing to support the diagnosis of probable CAA may be performed in circumstances when the above criteria are not met.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow up brain MRI
         </strong>
         – Follow-up imaging, typically three to six months after the acute event, may show resolution of the acute hemorrhage and help exclude underlying alternative causes. Interval development of subclinical neuroimaging findings, namely strictly lobar CMB or cSS, may provide further support for the diagnosis of CAA. (See
         <a class="local">
          'Microbleeds'
         </a>
         below and
         <a class="local">
          'Cortical superficial siderosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain biopsy
         </strong>
         – Brain biopsies are done rarely for the diagnosis of CAA. However, brain tissue may be obtained during surgical evacuation of select acute lobar hemorrhages. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis", section on 'Subsequent imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evacuated hematoma specimens and accompanying leptomeningeal or parenchymal tissue from older adult patients should routinely be examined with Congo red stain or beta-amyloid immunostain for CAA. Based upon data from a postmortem model, nearly all blocks of tissue from brains with CAA-related hemorrhage demonstrate some degree of CAA [
         <a href="#rid3">
          3
         </a>
         ], often with evidence of advanced disease such as complete amyloid replacement of the smooth muscle layer or the appearance of vessel breakdown [
         <a href="#rid61">
          61-63
         </a>
         ]. Signs of advanced disease are rare in single-tissue specimens from asymptomatic older adult brains; thus, their presence points toward a degree of CAA severe enough to cause hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebrospinal fluid analysis
         </strong>
         – Up to a 50 percent reduction in levels of cerebrospinal fluid (CSF) amyloid beta 42 and beta 40 protein have been found in patients with CAA [
         <a href="#rid64">
          64
         </a>
         ]. In combination with the finding of mildly increased total tau levels, CSF analysis distinguished patients with CAA from normal controls with a high degree of accuracy. Similar results were obtained in an independent study [
         <a href="#rid65">
          65
         </a>
         ]. We obtain CSF when the imaging diagnosis is uncertain and when confirming the diagnosis may affect clinical decisions, such as whether to give or withhold antithrombotic treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positron emission tomography
         </strong>
         – Positron emission tomography (PET) using 11C-Pittsburgh compound B (PIB), a ligand that binds to beta-amyloid, demonstrates increased uptake in patients with CAA-related hemorrhage compared with normal controls [
         <a href="#rid66">
          66,67
         </a>
         ]. Another PET study of the amyloid ligand florbetapir showed elevated retention in patients with CAA but not hypertension-related intracerebral hemorrhages [
         <a href="#rid68">
          68
         </a>
         ]. Compared with patients with Alzheimer disease, median binding of PIB is lower in CAA and may differ in its distribution. Current and future hemorrhagic lesions in patients with CAA appear to occur preferentially in local regions of concentrated amyloid detected by PIB [
         <a href="#rid69">
          69,70
         </a>
         ]. PET imaging is typically used in research settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – There is no clearly defined clinical role for genetic testing in sporadic CAA. In particular, apolipoprotein E (
         <em>
          APOE
         </em>
         ) genotype is neither sensitive nor specific for the diagnosis of CAA, as the epsilon 2 (e2) and epsilon 4 (e4) alleles are present in only a subset of patients [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2901772631">
         <span class="h2">
          Acute management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute CAA-related hemorrhage is treated like other acute nontraumatic intracerebral hemorrhages. Of note, surgical biopsy or hematoma resection appears to carry little or no additional risk in CAA compared with other types of ICH and can be performed when indicated [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H121044077">
         <span class="h2">
          Prevention of recurrent hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Survivors of lobar hemorrhage and patients with other clinical manifestations of CAA are at risk for future hemorrhagic complications (see
         <a class="local">
          'Prognosis'
         </a>
         below). This risk should be factored into decision-making when assessing the risks and benefits of other medications for patients with CAA.
        </p>
        <p class="headingAnchor" id="H1253548558">
         <span class="h3">
          Managing anticoagulant and antiplatelet medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the risk of spontaneous lobar hemorrhage in patients with CAA, we weigh the risks and benefits of using of anticoagulant and antiplatelet agents at an individual-level, in agreement with guidelines from the American Heart Association [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
         The major determinants of ICH risk in CAA patients are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of prior ICH
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of particular CAA-associated imaging features such as disseminated cSS (see
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Class of agent used (highest ICH risk with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , then the direct oral anticoagulants [DOACs; also called non-vitamin K antagonist oral anticoagulants, or NOACs], then antiplatelet agents, and lowest with no agent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duration of treatment
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         in particular increases both the frequency (approximately 7- to 10-fold) and severity (approximately 60 percent mortality) of cerebral hemorrhage [
         <a href="#rid73">
          73-75
         </a>
         ].
        </p>
        <p>
         The benefit of anticoagulants or antiplatelets is determined by the strength of the clinical indication and the availability of alternative treatments. In select patients with compelling indications for anticoagulation due to high risk of thromboembolism and absence of alternatives, anticoagulation may be used after discussion with the patient regarding risks and benefits. We reserve anticoagulation in CAA patients for those at high-risk for thromboembolic complications related to specific indications. These may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer-related thrombophilia with high risk of or prior venous thromboembolism (see
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercoagulable (acquired and inherited) conditions (see
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mechanical prosthetic heart valve replacement (see
         <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">
          "Antithrombotic therapy for mechanical heart valves"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other temporary high-risk indications for anticoagulation (see
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion", section on 'Postprocedure management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">
          "Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because ICH risk is a function of antithrombotic treatment duration as well as type, we recommend in these situations the shortest and least intense treatment course that is still compatible with effective thrombosis prevention.
        </p>
        <p>
        </p>
        <p>
         In other patients, we pursue alternatives to anticoagulation, based on indication.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atherosclerotic disease
         </strong>
         – We reserve
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for selected patients with CAA who have clear indications for antiplatelet therapy. Aspirin appears to increase the risk of hemorrhage but to a lesser extent than anticoagulants [
         <a href="#rid76">
          76
         </a>
         ]. However, some data in patients with established atherosclerotic risk factors suggest antiplatelet use may not increase the risk of ICH recurrence. In an open-label trial of 537 patients with a history of occlusive vascular disease who developed ICH, patients were assigned to restart or avoid antiplatelet therapy at a median of 76 days following ICH [
         <a href="#rid77">
          77
         </a>
         ]. At a median two-year follow-up, there was a trend toward less ICH recurrence in those assigned to restart antiplatelet therapy (4 versus 9 percent; hazard ratio 0.51, 95% CI 0.25-1.03).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrial fibrillation
         </strong>
         – The management of atrial fibrillation in patients with CAA-related ICH is uncertain. Left atrial appendage closure is a reasonable treatment option for individuals with CAA who are at high risk for atrial fibrillation-related cardioembolic stroke [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/928.html" rel="external">
          "Atrial fibrillation: Left atrial appendage occlusion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">
          "Atrial fibrillation in adults: Selection of candidates for anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, some retrospective studies have reported good outcomes for patients with atrial fibrillation who were restarted on anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         after recovery from an anticoagulant-related intracerebral hemorrhage [
         <a href="#rid79">
          79
         </a>
         ]. Conclusions from these retrospective analyses are limited by the likelihood of indication bias regarding which patients were or were not re-anticoagulated, but they offer a rationale for randomized trials to address this question [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The DOACs appear at least as effective as
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         for prevention of ischemic strokes in patients with atrial fibrillation and confer lower risks for ICH. While they have not been studied for this indication, some experts use these agents (
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         ,
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ) for patients with atrial fibrillation and CAA who are at high risk for both ischemic and hemorrhagic stroke.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other potential alternatives to anticoagulation in high-risk patients with atrial fibrillation are discussed separately.
        </p>
        <p>
        </p>
        <p>
         Some nonsteroidal anti-inflammatory medications have weak antithrombotic properties. We prefer the nonacetylated salicylates (eg,
         <a class="drug drug_general" data-topicid="10124" href="/z/d/drug information/10124.html" rel="external">
          magnesium salicylate
         </a>
         ) drugs over other nonsteroidal anti-inflammatory drugs as they do not appear to affect platelet function.
        </p>
        <p class="headingAnchor" id="H2932996599">
         <span class="h3">
          Thrombolytic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely offer thrombolytic therapy for indications such as acute ischemic stroke, myocardial infarction, or pulmonary embolism in patients with a history of CAA-related ICH. Intravenous thrombolysis for ischemic stroke is contraindicated in patients with a history of ICH [
         <a href="#rid81">
          81
         </a>
         ]. Endovascular mechanical thrombectomy may be an option for patients with a history of lobar ICH. Because patients with CAA are at risk of hemorrhagic complications from thrombolytic therapy, the risks and benefits of acute therapies should be discussed with patients or their proxies whenever possible.
        </p>
        <p>
         A large trial evaluating the use of tissue-type plasminogen activator for acute myocardial infarction identified severe CAA at postmortem examination in two of five patients with intracerebral hemorrhagic complications [
         <a href="#rid82">
          82
         </a>
         ]. Additionally, in one analysis of acute ischemic stroke, patients reported an association between number of cortical microbleeds and an elevated risk of hemorrhagic complications after systemic thrombolysis [
         <a href="#rid83">
          83
         </a>
         ]. However, the specific treatment benefits of thrombolytic therapy in such patients were not assessed.
        </p>
        <p class="headingAnchor" id="H2819600840">
         <span class="h3">
          Blood pressure control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the vascular pathology in CAA does not appear primarily driven by hypertension, control of blood pressure within normal limits is nonetheless advisable. We use intensive blood pressure goals, as tolerated  (
         <a class="graphic graphic_table graphicRef117101" href="/z/d/graphic/117101.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3823.html" rel="external">
          "Antihypertensive therapy for secondary stroke prevention", section on 'Patients with intracerebral hemorrhage'
         </a>
         .)
        </p>
        <p>
         Support for lowering of blood pressure in patients diagnosed with CAA came from a secondary analysis of data from the
         <a class="drug drug_general" data-topicid="9758" href="/z/d/drug information/9758.html" rel="external">
          Perindopril
         </a>
         Protection Against Recurrent Stroke Study (PROGRESS) trial [
         <a href="#rid15">
          15
         </a>
         ]. At a median follow up of 3.9 years, those assigned to active treatment (perindopril plus
         <a class="drug drug_general" data-topicid="8557" href="/z/d/drug information/8557.html" rel="external">
          indapamide
         </a>
         ) had a 77 percent reduction (3 versus 13 events) of probable CAA-related ICH. These results are consistent with observational data showing reduced risk of ICH recurrence among ICH survivors with lower ambulatory blood pressures [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196826676">
         <span class="h3">
          Managing statin use
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not withhold statin agents for most CAA patients when otherwise indicated. While a number of studies have found an inverse relationship between total and low-density lipoprotein cholesterol and the risk of ICH [
         <a href="#rid84">
          84,85
         </a>
         ], treatment with statins does not appear to increase the risk of primary ICH or to negatively impact prognosis according to a number of studies and meta-analyses [
         <a href="#rid86">
          86-89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129071.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Management of statins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3483254397">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lobar hemorrhage in general is associated with features that are both favorable (their superficial location and tendency to spare the ventricles) and unfavorable to outcome (older age and somewhat larger hematoma size) [
         <a href="#rid90">
          90-92
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mortality
         </strong>
         – Overall mortality in acute lobar hemorrhage due to CAA is in the range of 10 to 30 percent [
         <a href="#rid91">
          91,92
         </a>
         ], with the best prognosis for patients with smaller hematomas (&lt;50 mL) and higher level of consciousness on admission (Glasgow coma scale ≥8).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence
         </strong>
         – CAA carries a substantially higher risk of hemorrhage recurrence than for hypertensive hemorrhage. In two case series of ICH survivors, recurrence rates were 21 percent at 2 years and 24 percent at a median 2.6 years, respectively [
         <a href="#rid34">
          34,93
         </a>
         ]. Another report of 104 survivors of primary lobar ICH found that patients with history of ICH prior to the index event were at approximately six times the risk as those without a previous history. The risk for recurrent ICH was even higher in those who had more than one prior ICH [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recurrent hemorrhages have a tendency to arise in areas of prior hemorrhage [
         <a href="#rid44">
          44
         </a>
         ]. Areas of high amyloid deposition on amyloid imaging appear to predict sites for future hemorrhage [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several factors influence the risk of recurrent ICH in patients diagnosed with CAA.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Burden of traditional risk factors for ICH
         </strong>
         – Factors typically associated with an elevated risk of recurrent ICH among patients with spontaneous ICH such as hypertension, older age, and use of antithrombotic medications have also been associated with an increased risk of recurrent ICH among patients with CAA [
         <a href="#rid75">
          75,94,95
         </a>
         ]. These risk factors are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/129071.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Presence of chronic hemorrhagic features on diagnostic imaging
         </strong>
         – Recurrent ICH is more likely with increasing number of CMBs and disseminated cSS (see
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         below). In a study of 94 consecutive survivors of primary lobar hemorrhage, the three-year cumulative risk of recurrent hemorrhage for patients with one, two, three to five, and six or greater CMBs on the baseline gradient-echo MRI was 14, 17, 38, and 51 percent, respectively (hazard ratio 1.7, 95% CI 1.2-2.4 for each increase in category) [
         <a href="#rid96">
          96
         </a>
         ].
         <em>
         </em>
         In a study of 118 patients diagnosed with CAA (104 with a symptomatic lobar ICH), the cumulative risk of new ICH at four years was 74 percent for the 27 individuals with disseminated cSS (defined as involving more than three cortical sulci) versus only 25 percent for the 77 without siderosis at baseline [
         <a href="#rid97">
          97
         </a>
         ]. Similarly, the presence of cSAH in patients with CAA is associated with an increased risk of recurrent ICH [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Early evidence suggests that patients with ICH who are diagnosed with probable CAA based on nonhemorrhagic imaging findings such as dilated perivascular spaces or T2-weighted white matter hyperintensities in a multispot pattern might have a lower risk of subsequent hemorrhage than patients with chronic hemorrhagic imaging features. In a single center study of 443 patients with acute ICH, probable CAA was diagnosed using the Boston criteria version 1.5 in 82 patients (19 percent) and by version 2.0 in 102 patients (23 percent) [
         <a href="#rid99">
          99
         </a>
         ]. The five-year ICH recurrence risk was higher for patients with CAA identified by version 1.5 criteria (48 versus 41 percent). Among 20 patients who fulfilled Boston criteria version 2.0 but not version 1.5, the five-year ICH recurrence risk was 9 percent. Most of these patients met version 2.0 criteria for probable CAA based on enlarged perivascular spaces  (
         <a class="graphic graphic_table graphicRef139328" href="/z/d/graphic/139328.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          APOE status
         </strong>
         – Carriers of the e2 or e4
         <em>
          APOE
         </em>
         alleles are also at increased risk compared with the more common
         <em>
          APOE
         </em>
         e3/e3 genotype [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="local">
          'Genetic susceptibilities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incident dementia
         </strong>
         – The association of subsequent dementia in patients with lobar ICH may reflect an elevated rate of ICH recurrence and/or the relationship of CAA with cognitive impairment. In a study of 255 patients with lobar and nonlobar ICH followed for five years, patients with lobar ICH had higher rates of dementia (36 versus 21 percent) and higher rates of disability (60 versus 31 percent) compared with those with nonlobar ICH [
         <a href="#rid100">
          100
         </a>
         ]. This finding is consistent with a prior study of 218 ICH survivors with one-year incidence of new-onset dementia of 23.4 percent for lobar ICH versus 9.2 percent for nonlobar ICH [
         <a href="#rid101">
          101
         </a>
         ]. In another cohort of 97 patients with lobar ICH, the rate of dementia after median 2.5-year follow-up was 26 percent [
         <a href="#rid102">
          102
         </a>
         ]. (See
         <a class="local">
          'Cognitive impairment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3617232616">
         <span class="h1">
          INCIDENTAL CHRONIC IMAGING FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CAA are frequently asymptomatic unless they develop a specific clinical episode. Evidence suggestive of CAA may be identified in asymptomatic patients who undergo brain MRI for unrelated symptoms (eg, chronic headaches).
        </p>
        <p class="headingAnchor" id="H2245220324">
         <span class="h2">
          Microbleeds
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic evidence of tiny asymptomatic bleeding within the brain can be detected on brain MRI and may reflect CAA. These microbleeds (or microhemorrhages) appear as 2 to 10 mm focal areas of hemosiderin deposition on gradient echo or other T2*-weighted sequences  (
         <a class="graphic graphic_diagnosticimage graphicRef119376" href="/z/d/graphic/119376.html" rel="external">
          image 7
         </a>
         ). In population-based studies, cerebral microbleeds are detected in 5 to 23 percent of older individuals [
         <a href="#rid103">
          103-106
         </a>
         ].
        </p>
        <p>
         Microbleeds can arise from small-vessel disease (CAA or hypertensive vasculopathy) and may represent a milder and somewhat distinct manifestation from overt (macro-)hemorrhage. Analysis of CAA patients in a neuroimaging study who underwent autopsy showed those with a large number of microbleeds had thicker-walled vessels due to beta-amyloid deposition compared with patients with a lower proportion or absence of microbleeds [
         <a href="#rid107">
          107
         </a>
         ]. Microbleeds are also more prevalent among those using antiplatelet agents than nonusers [
         <a href="#rid108">
          108,109
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and differential diagnosis
         </strong>
         – Focal areas of hemosiderin deposition on MRI should be reviewed with some care since lesions and structures other than hemorrhage can produce signal dropout. These include mineralization (particularly of the basal ganglia), flow-void from a cortical vessel, or adjacent air in the nasal sinuses. When establishing the presence of at least two hemorrhages, lesions that do not clearly represent independent hemorrhagic foci (for example, small blood deposits close to a larger hematoma) should not be counted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cerebral microbleeds are not specific for CAA as they can be seen in multiple conditions. Such conditions may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension [
         <a href="#rid110">
          110,111
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebral cavernous malformations [
         <a href="#rid112">
          112
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coagulopathy [
         <a href="#rid113">
          113,114
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thrombocytopenia [
         <a href="#rid115">
          115,116
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticoagulant medications [
         <a href="#rid117">
          117
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Central nervous system vasculitis [
         <a href="#rid118">
          118
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infective endocarditis [
         <a href="#rid119">
          119
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         End-stage kidney failure [
         <a href="#rid120">
          120
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Traumatic brain injury [
         <a href="#rid121">
          121
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior cardiac surgery [
         <a href="#rid122">
          122
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While microbleeds in general are not specific to CAA, cortical microbleeds (CMBs; (ie, those restricted to the cerebral cortex or superficial cerebellar regions [cerebellar cortex and vermis]), suggest CAA [
         <a href="#rid110">
          110,111
         </a>
         ]. In contrast, microbleeds that involve the basal ganglia, thalamus, or pons are believed to result from hypertensive microangiopathy. The association between lobar microbleeds and
         <em>
          APOE
         </em>
         e4 in the Rotterdam and other studies support the hypothesis that these more superficial lesions often originate from CAA [
         <a href="#rid30">
          30,105,106,123,124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management and prognosis
         </strong>
         – For patients with acute ischemic stroke and a known history of CAA with CMBs only (ie, without a history of lobar hemorrhage or cortical superficial siderosis), we do not withhold systemic intravenous thrombolytic therapy if they otherwise meet eligibility criteria  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 4
         </a>
         ), in agreement with guideline statements from the American Heart Association [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Over the long-term, the risk of incident hemorrhage in patients with multiple CMBs is nonetheless substantial [
         <a href="#rid125">
          125
         </a>
         ]. Thus, other measures for primary prevention are similar as for patients with an ICH presentation. (See
         <a class="local">
          'Prevention of recurrent hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CMBs are associated with an elevated risk of death. One study found that an incidental finding of multiple CMBs in an older adult was associated with a sevenfold risk of stroke-related death compared to individuals without CMBs [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3571990375">
         <span class="h2">
          Cortical superficial siderosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of chronic bleeding at the surface of the brain seen on imaging as foci of cSS may be seen in patients with CAA. They likely reflect the chronic form of acute convexity subarachnoid hemorrhage  (
         <a class="graphic graphic_diagnosticimage graphicRef130369" href="/z/d/graphic/130369.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid55">
          55,127,128
         </a>
         ]. cSS is typical at the convexities of the cerebral hemispheres in patients with CAA but may also be found along the cerebellar folia [
         <a href="#rid51">
          51
         </a>
         ]. cSS is frequently found in CAA patients with microbleeds and appears to signal higher risk for future ICH, particularly disseminated cSS. (See
         <a class="local">
          'Microbleeds'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
         cSS typically is an asymptomatic imaging finding but is also detected in many CAA patients who present with transient neurologic symptoms [
         <a href="#rid128">
          128,129
         </a>
         ]. (See
         <a class="local">
          'Transient focal neurologic episodes'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and differential diagnosis
         </strong>
         – cSS is common in patients with CAA (40 to 60 percent) but is unusual in patients with ICH of other cause (0 to 4 percent) [
         <a href="#rid55">
          55,129
         </a>
         ]. However, cSS and superficial siderosis involving the cerebellum or brainstem can also arise from several other unrelated causes. These are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128433.html" rel="external">
          "Superficial siderosis", section on 'Etiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with isolated hemorrhagic imaging findings such as a single CMB or equivocal focus of cSS may develop progressive subclinical findings to further support the diagnosis of CAA. As an example, in one cohort of 118 patients with probable CAA who underwent follow-up imaging at a mean interval of 2.2 years, progression of cSS was found in 28 percent and new CMBs were found in 18 percent [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management and prognosis
         </strong>
         – For patients with acute ischemic stroke and a known history of CAA with cSS, we do not routinely offer systemic thrombolytic therapy. cSS represents an imaging marker of prior ICH, a contraindication for intravenous thrombolysis  (
         <a class="graphic graphic_table graphicRef71462" href="/z/d/graphic/71462.html" rel="external">
          table 4
         </a>
         ). Endovascular mechanical thrombectomy may be an option for such patients when treatment benefits are felt to outweigh the hemorrhagic risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with cSS and a history of ischemic stroke, we individualize the use of antithrombotic therapy based on overall risks and benefits. Retrospective data on such patients who resume antiplatelets or anticoagulants have shown a higher subsequent risk of recurrent ischemic stroke than hemorrhage, suggesting that use of antithrombotics may be considered [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The approach to primary stroke prevention in patients with cSS is similar as that for patients with a prior ICH presentation. (See
         <a class="local">
          'Prevention of recurrent hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         cSS is associated with poor functional outcome in CAA [
         <a href="#rid132">
          132
         </a>
         ]. Disseminated cSS in CAA appears to be an independent predictor of recurrent ICH [
         <a href="#rid97">
          97,133
         </a>
         ], and radiologic progression of cSS on serial imaging has been associated with an increased risk of subsequent ICH [
         <a href="#rid130">
          130
         </a>
         ]. cSS has also associated with an elevated risk of epilepsy in patients with CAA [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1108478742">
         <span class="h2">
          Nonhemorrhagic imaging findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonhemorrhagic findings on brain MRI may also be found in patients with CAA [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute ischemic micro-infarcts
         </strong>
         – Asymptomatic punctate hyperintense lesions on diffusion-weighted image (DWI) sequencing are occasionally found in patients with CAA [
         <a href="#rid135">
          135
         </a>
         ]. In one retrospective review of brain MRIs from 78 patients with probable CAA, subacute infarcts were identified on DWI in 15 percent [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brain atrophy
         </strong>
         – Cerebral atrophy of white matter is associated with CAA. In one study, white matter volume was lower in patients with CAA than age-matched patients with Alzheimer disease and healthy controls [
         <a href="#rid137">
          137
         </a>
         ]. In CAA patients, atrophy was most pronounced in occipital regions and was more severe in those with higher cortical microbleeds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          White matter hyperintensities
         </strong>
         – Chronic white matter hyperintensities on T2-weighted sequences of brain MRI frequently represent small-vessel disease related to multiple conditions. Imaging patterns suggestive of CAA include the "multispot" pattern of multiple (ie, &gt;10), typically bilateral lesions with a round or ovoid appearance [
         <a href="#rid138">
          138
         </a>
         ]. In more advanced cases, white matter hyperintensities may be confluent. Such prominent findings may be seen preferentially in the subcortical parietal and occipital lobes of patients with advanced CAA [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Centrum semiovale perivascular spaces
         </strong>
         – Dilated perivascular spaces are identified typically on brain MRI as hyperintense lesions on T2-weighted sequences. They have been associated with vascular disease and aging, but the presence of multiple (&gt;20) dilated perivascular spaces in the subcortical centrum semiovale regions has been associated with CAA with and without ICH [
         <a href="#rid57">
          57,133,140-142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1040317013">
         <span class="h1">
          TRANSIENT FOCAL NEUROLOGIC EPISODES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A less common clinical manifestation of CAA is transient focal neurologic episodes (TFNE) [
         <a href="#rid143">
          143-145
         </a>
         ]. These have also been called "amyloid spells."
        </p>
        <p class="headingAnchor" id="H2872183857">
         <span class="h2">
          Pathogenesis and clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients report recurrent, brief, and often stereotyped spells of weakness, numbness, paresthesias, or other cortical symptoms that can spread smoothly over contiguous body parts over several minutes. In one cohort, transient neurologic symptoms occurred in 14 percent of patients with CAA, and positive symptoms (positive visual aura, limb jerking) were as common as negative symptoms (vision loss, limb weakness, dysphasia) [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
         These episodes may reflect abnormal activity (ie, cortical spreading depression) of the surrounding cortex typically in response to the small hemorrhages [
         <a href="#rid147">
          147
         </a>
         ]. In one study, CAA patients with cortical superficial siderosis (cSS) or convexity subarachnoid hemorrhage (cSAH) were more likely to have transient neurologic symptoms compared with CAA patients without these symptoms (50 versus 19 percent) [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3114161190">
         <span class="h2">
          Evaluation and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The description of TFNEs can be similar to other transient neurologic attacks such as transient ischemic attacks (TIAs), seizures, and migraine auras.
        </p>
        <p>
         Clinical features more suggestive of TFNE over other diagnoses include the smooth spread of the symptoms over minutes and the stereotypic recurrence of symptoms over time. Symptoms of TFNE tend to localize to the site of a cSAH, prior lobar hemorrhage, or focus of cSS [
         <a href="#rid148">
          148
         </a>
         ]. (See
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         above.)
        </p>
        <p>
         Additionally, diagnostic evaluation at the time of acute symptoms can support the diagnosis of TFNE and exclude alternative causes. This may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain MRI with gradient echo or other T2*-weighted sequences to identify cSAH, cSS, or cortical microbleeds (CMBs) in the region of cortex corresponding to TFNE symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular imaging to exclude hemodynamically significant stenosis in the relevant vascular supply
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electroencephalogram showing no epileptiform activity or seizure in the brain region corresponding to TFNE symptoms
        </p>
        <p>
        </p>
        <p>
         Additional testing may be performed to exclude TIA or ischemic stroke if indicated by clinical features or patient risk profile. (See
         <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">
          "Differential diagnosis of transient ischemic attack and acute stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1123.html" rel="external">
          "Initial evaluation and management of transient ischemic attack and minor ischemic stroke"
         </a>
         .)
        </p>
        <p>
         Features that support an alternative diagnosis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TIAs may present in a patient with vascular risk factors as sudden loss of focal neurologic function attributable to a specific cerebrovascular arterial territory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures may occur in a patient with a history of epilepsy or seizures as focal or diffuse symptoms. They may be associated with temporary postictal weakness or other loss of function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Migraines typically occur in younger patients with a prior history of migraines. Neurologic symptoms typifying the aura may wax over minutes prior to the onset of a headache.
        </p>
        <p>
        </p>
        <p>
         The differential diagnosis and evaluation of patients with transient neurologic episodes is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">
          "Differential diagnosis of transient ischemic attack and acute stroke", section on 'Transient neurologic events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1137.html" rel="external">
          "Differential diagnosis of transient ischemic attack and acute stroke", section on 'Distinguishing transient attacks'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2204204595">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Avoiding misdiagnosis is critical since the administration of antithrombotics for TFNE symptoms presumed to be a TIA may increase the risk of hemorrhagic stroke from CAA [
         <a href="#rid148">
          148
         </a>
         ]. In one series, transient neurologic symptoms in a patient with CAA appeared to predict a high early risk of symptomatic intracerebral hemorrhage, which occurred in 50 percent of patients over a median follow-up period of 14 months [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
         TFNE are typically brief and self-limited but may recur. Patients should be reassured that TFNE that recur typically resolve within weeks [
         <a href="#rid147">
          147
         </a>
         ]. Medications used for seizures or migraine such as
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         or
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         have been used for those with recurrent or bothersome attacks [
         <a href="#rid147">
          147,149
         </a>
         ].
        </p>
        <p>
         Other general measures, applicable to patients with hemorrhagic features of CAA, are discussed separately. (See
         <a class="local">
          'Prevention of recurrent hemorrhage'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2804649907">
         <span class="h1">
          CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebral amyloid angiopathy-related inflammation (CAA-ri) appears to represent a distinct manifestation of CAA characterized by an inflammatory response to amyloid deposition in the brain with subacute and often progressive neurologic symptoms [
         <a href="#rid150">
          150,151
         </a>
         ].
        </p>
        <p>
         CAA-ri may be a milder form of a condition called Abeta-related angiitis. CAA-ri is characterized by perivascular inflammation, while Abeta-related angiitis is a true vasculitis with inflammation throughout the vessel wall [
         <a href="#rid152">
          152-154
         </a>
         ]. These two inflammatory syndromes share similar clinical presentations, imaging properties, and response to treatment, except that Abeta-related angiitis typically requires more aggressive immunosuppressive treatment. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4195244470">
         <span class="h2">
          Clinical and diagnostic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of a CAA-ri syndrome is that of acute or subacute cognitive decline rather than hemorrhage [
         <a href="#rid155">
          155,156
         </a>
         ]. Patients or family members may report memory impairment, personality changes, confusion, or alterations in level of consciousness. Seizures, new and persistent headaches, and focal and progressive neurologic signs are common.
        </p>
        <p>
         Patients with CAA-ri are younger than those with other manifestations of CAA. In a systematic review of 21 studies that included 378 patients with CAA-ri, the mean age at diagnosis was 66 years [
         <a href="#rid157">
          157
         </a>
         ]. Cognitive decline was reported in 70 percent, encephalopathy in 54 percent, focal neurologic symptoms in 55 percent, headaches in 31 percent, and seizures in 37 percent.
        </p>
        <p>
         The differential diagnosis includes primary, viral, and autoimmune encephalitides as well as cerebral neoplasm and other causes of rapidly progressive dementia [
         <a href="#rid158">
          158-160
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8230.html" rel="external">
          "Primary angiitis of the central nervous system in adults", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
         Diagnostic studies in this setting typically include brain MRI with contrast, serologic, and cerebrospinal fluid (CSF) analysis. Brain biopsy may be performed both to make a positive diagnosis of CAA-related inflammation as well to exclude other conditions. Findings that support the diagnosis of CAA-ri include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain MRI typically shows a (potentially reversible) leukoencephalopathy consisting of patchy or confluent white matter hyperintensities on T2-weighted sequences, characteristically in subcortical white matter, often asymmetric; multiple microbleeds and/or cortical superficial siderosis are seen on gradient echo sequences  (
         <a class="graphic graphic_diagnosticimage graphicRef55227" href="/z/d/graphic/55227.html" rel="external">
          image 8
         </a>
         ). Gadolinium enhancement may be found in up to half of cases [
         <a href="#rid157">
          157,161
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiography or magnetic resonance angiography does not show evidence of large- or medium-vessel vasculitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuropathology shows perivascular inflammation with multinucleated giant cells that is associated with amyloid-laden vessels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythrocyte sedimentation rate and C-reactive protein are normal [
         <a href="#rid156">
          156
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CSF analysis may be normal but often shows a pleocytosis and/or mildly elevated protein. Anti-amyloid autoantibodies have been detected in the CSF during the acute phase of inflammation and return to control levels during remission [
         <a href="#rid162">
          162-164
         </a>
         ]. CSF assay for anti-amyloid antibodies is not yet commercially available but may eventually emerge as a diagnostic test. Clinical and radiographic improvement may occur with immunosuppressive treatment [
         <a href="#rid150">
          150,151,156,165
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The diagnosis of CAA-ri is made in symptomatic patients with diagnostic imaging evidence of inflammation and hemorrhagic features of CAA who have undergone evaluation to exclude other sources  (
         <a class="graphic graphic_table graphicRef118977" href="/z/d/graphic/118977.html" rel="external">
          table 5
         </a>
         ). A validation study of proposed criteria for the diagnosis of probable CAA-related inflammation showed high sensitivity (82 percent) and specificity (97 percent) [
         <a href="#rid161">
          161
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2163281224">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically treat patients with suspected CAA-related inflammation with a course of high-dose glucocorticoids followed by a gradual oral taper. Our treatment protocol is usually
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         1000 mg per day for three to five days, followed by an oral glucocorticoid taper over approximately 6 to 12 weeks. A repeat brain MRI scan approximately four to six weeks after treatment onset use clinical symptoms and changes in the subcortical white matter hyperintensities as evidence for treatment response. Although glucocorticoid therapy is most often used in this setting [
         <a href="#rid164">
          164,166-168
         </a>
         ], other immunosuppressive treatments, such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, have also been used with a favorable response in isolated cases [
         <a href="#rid156">
          156,169,170
         </a>
         ].
        </p>
        <p>
         While data are limited, available evidence from observational studies supports treating inflammatory forms of CAA with immunosuppressive therapy [
         <a href="#rid151">
          151,166-171
         </a>
         ]. In one series of 48 patients with CAA-related inflammation, those who were treated with immunosuppression (mostly glucocorticoids) were more likely to improve clinically (94 versus 50 percent) and radiographically (86 versus 29 percent) [
         <a href="#rid171">
          171
         </a>
         ]. Treated patients were also less likely to have recurrent symptoms during a median of 2.7 years of follow-up (26 versus 71 percent).
        </p>
        <p>
         The response to therapy may be seen within the first few months and may be more durable when glucocorticoids are tapered slowly. In an observational study of 113 patients with CAA-related inflammation of whom 88 percent received immunosuppressive therapy, clinical recovery was reported by three months in 70 percent and resolution of inflammatory features on neuroimaging occurred in 45 percent [
         <a href="#rid166">
          166
         </a>
         ]. By 12 months, the rates of clinical and radiologic recovery were 84 and 77 percent, respectively. Symptomatic recurrence was likelier in patients treated with high-dose pulse of intravenous glucocorticoids alone than those treated with pulse intravenous glucocorticoids followed by a gradual oral glucocorticoid taper (hazard ratio 4.68, 95% CI 1.57–13.93).
        </p>
        <p>
         Additional measures to mitigate the associated risks of future bleeding associated with CAA should be based on the risks associated with hemorrhagic features. (See
         <a class="local">
          'Prevention of recurrent hemorrhage'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3606214674">
         <span class="h1">
          COGNITIVE IMPAIRMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advanced CAA is associated with cognitive impairment. The majority of patients diagnosed with CAA appear to have cognitive impairment in at least one domain on neuropsychological testing [
         <a href="#rid17">
          17
         </a>
         ]. An autopsy series found that moderate to severe CAA (present in one-third of the study population) was associated with faster rates of decline in global cognition, perceptual speed, episodic memory, and semantic memory, independently of age, sex, education, Alzheimer disease pathology, and other potential covariates [
         <a href="#rid172">
          172
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1365561618">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of cognitive impairment in CAA may be multifactorial, with contributions from both vascular injury and Alzheimer disease pathology.
        </p>
        <p class="headingAnchor" id="H1822776961">
         <span class="h3">
          Relationship to Alzheimer disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAA is common in conjunction with Alzheimer disease, appearing in moderate to severe form in 30 of 117 (26 percent) Alzheimer disease brains in an autopsy series; CAA with hemorrhage occurred in six (5.1 percent) [
         <a href="#rid5">
          5,173
         </a>
         ]. Another autopsy study found that patients with both CAA and Alzheimer disease had more severe cognitive impairment than patients with Alzheimer disease alone [
         <a href="#rid174">
          174
         </a>
         ]. Similarly, an MRI study in Alzheimer disease patients found that the presence of multiple microbleeds was associated with worse cognitive performance [
         <a href="#rid175">
          175
         </a>
         ]. However, only about 25 percent of CAA patients appear to have clinical histories of dementia prior to their first hemorrhage [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5071.html" rel="external">
          "Clinical features and diagnosis of Alzheimer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2784672023">
         <span class="h3">
          Relationship to vascular dementia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cerebrovascular disease may contribute to cognitive impairment in patients with CAA. Studies in population- and hospital-based subjects have correlated the number and presence of microbleeds with cognitive impairment and dementia, raising the possibility that these lesions are contributors to neurologic dysfunction, as well as markers of small-vessel disease [
         <a href="#rid176">
          176,177
         </a>
         ]. In one study of patients who underwent MRI because of transient ischemic attack or stroke, a finding of lobar microhemorrhage but not deep microhemorrhage was associated with cognitive impairment [
         <a href="#rid178">
          178
         </a>
         ].
        </p>
        <p>
         Additionally, clinically silent acute or subacute cerebral infarcts on diffusion-weighted imaging have been detected in 15 to 23 percent of patients with CAA [
         <a href="#rid136">
          136,179
         </a>
         ], and cerebral microinfarcts on T1 and fluid-attenuated inversion recovery (FLAIR) imaging have been found in 35 to 39 percent [
         <a href="#rid180">
          180,181
         </a>
         ]. These data are consistent with autopsy and imaging studies showing an association between CAA severity and volume of white matter hyperintensity and/or microinfarct burden [
         <a href="#rid143">
          143,182-186
         </a>
         ]. Cognitive impairment in CAA is also associated with ultrastructural white matter abnormalities measured by diffusion-tensor imaging-based methods [
         <a href="#rid187">
          187,188
         </a>
         ].
        </p>
        <p>
         Vascular dementia is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5085.html" rel="external">
          "Etiology, clinical manifestations, and diagnosis of vascular dementia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1130748489">
         <span class="h2">
          Evaluation and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation and management of patients with cognitive impairment in the setting of CAA does not differ from other settings. Supportive care is the mainstay for patients with cognitive impairment related to CAA, like that of patients with other forms of cognitive impairment and dementia. This is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">
          "Management of the patient with dementia"
         </a>
         .)
        </p>
        <p>
         Other general measures, applicable to all patients with CAA, are discussed separately. (See
         <a class="local">
          'Prevention of recurrent hemorrhage'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3942323382">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">
          "Society guideline links: Stroke in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Cerebral amyloid angiopathy (CAA) is characterized by amyloid beta-peptide deposits within small- to medium-sized blood vessels of the brain and leptomeninges. CAA is an important cause of lobar intracerebral hemorrhage in older adults. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of probable CAA can be made with clinical evaluation and magnetic resonance imaging (MRI) of the brain  (
         <a class="graphic graphic_table graphicRef139328" href="/z/d/graphic/139328.html" rel="external">
          table 2
         </a>
         ). Follow-up MRI examinations may be helpful if the initial study is equivocal. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute intracerebral hemorrhage
         </strong>
         – The most common clinical manifestation of CAA is acute lobar intracerebral hemorrhage (ICH)  (
         <a class="graphic graphic_diagnosticimage graphicRef50480" href="/z/d/graphic/50480.html" rel="external">
          image 1
         </a>
         ). CAA-related lobar hemorrhages most commonly arise in posterior lobar brain regions. Because of their superficial location, CAA-related hemorrhages often extend beyond the brain tissue into the subarachnoid and subdural spaces and less frequently rupture into ventricles. (See
         <a class="local">
          'Acute intracerebral hemorrhage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of the risk of spontaneous lobar hemorrhage in patients with CAA, we weigh the risks and benefits of using of anticoagulant and antiplatelet agents at an individual level. We reserve anticoagulation in CAA patients for those at high risk for thromboembolic complications related to specific indications. (See
         <a class="local">
          'Managing anticoagulant and antiplatelet medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidental imaging features
         </strong>
         – Chronic evidence of asymptomatic bleeding and other imaging findings can be detected on brain MRI in CAA patients with or without lobar hemorrhage. (See
         <a class="local">
          'Incidental chronic imaging features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Microbleeds (or microhemorrhages) appear as 2 to 10 mm focal areas of hemosiderin deposition on gradient echo or other T2*-weighted sequences  (
         <a class="graphic graphic_diagnosticimage graphicRef119376" href="/z/d/graphic/119376.html" rel="external">
          image 7
         </a>
         ) and have an anatomic distribution similar to that of intracerebral hemorrhage, with a predilection for the cerebral cortex.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cortical superficial siderosis (cSS) can represent a focus of remote bleeding related to CAA  (
         <a class="graphic graphic_diagnosticimage graphicRef130369" href="/z/d/graphic/130369.html" rel="external">
          image 6
         </a>
         ) and is thought to be the chronic form of acute convexity subarachnoid hemorrhage.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nonhemorrhagic imaging findings such as ischemic microinfarcts, cerebral atrophy, white matter hyperintensities, and multiple dilated perivascular spaces may also be found in patients with CAA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transient focal neurologic episodes
         </strong>
         – Patients with CAA may present with transient focal neurologic episodes (TFNE) described as recurrent, brief, and often stereotyped spells of weakness, numbness, paresthesias, or other cortical symptoms. Symptoms spread smoothly over contiguous body parts over several minutes and tend to localize to the site of a prior lobar hemorrhage or focus of cSS. (See
         <a class="local">
          'Transient focal neurologic episodes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerebral amyloid angiopathy-related inflammation
         </strong>
         – Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a distinct manifestation of CAA. Patients present with acute or subacute cognitive decline, seizures, new persistent headaches, or other progressive neurologic signs  (
         <a class="graphic graphic_table graphicRef118977" href="/z/d/graphic/118977.html" rel="external">
          table 5
         </a>
         ); imaging demonstrates a patchy or confluent immediately subcortical leukoencephalopathy along with lobar microhemorrhages  (
         <a class="graphic graphic_diagnosticimage graphicRef55227" href="/z/d/graphic/55227.html" rel="external">
          image 8
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with suspected CAA-ri, we suggest treatment with a course of immunosuppressive therapy, most often with glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Cerebral amyloid angiopathy-related inflammation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognitive impairment
         </strong>
         – Advanced CAA is associated with cognitive impairment, which may reflect comorbid Alzheimer disease, vascular dementia, or both. (See
         <a class="local">
          'Cognitive impairment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997; 28:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 2018; 83:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arvanitakis Z, Leurgans SE, Wang Z, et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011; 69:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamara DM, Gangishetti U, Gearing M, et al. Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 2018; 62:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushik K, van Etten ES, Siegerink B, et al. Iatrogenic Cerebral Amyloid Angiopathy Post Neurosurgery: Frequency, Clinical Profile, Radiological Features, and Outcome. Stroke 2023; 54:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol 2009; 9:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm (Vienna) 2002; 109:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 2015; 525:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee G, Samra K, Adams ME, et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kellie JF, Campbell BCV, Watson R, et al. Amyloid-β (Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery. Stroke 2022; 53:e369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreiro JA, Ansbacher LE, Vinters HV. Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease. J Neurol 1989; 236:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broderick J, Brott T, Tomsick T, Leach A. Lobar hemorrhage in the elderly. The undiminishing importance of hypertension. Stroke 1993; 24:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010; 41:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Anderson CD, Battey TW, et al. Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage. JAMA 2015; 314:904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 2020; 16:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obici L, Demarchi A, de Rosa G, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozberg MG, van Veluw SJ, Frosch MP, Greenberg SM. Hereditary cerebral amyloid angiopathy, Piedmont-type mutation. Neurol Genet 2020; 6:e411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maat-Schieman ML, Radder CM, van Duinen SG, et al. Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol 1994; 88:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Etten ES, Gurol ME, van der Grond J, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016; 87:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melchor JP, McVoy L, Van Nostrand WE. Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein. J Neurochem 2000; 74:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Nostrand WE, Melchor JP, Cho HS, et al. Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem 2001; 276:32860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 2004; 279:20296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997; 41:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Rebeck GW, Vonsattel JP, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: Systematic review and meta-analyses. Neurology 2011; 77:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rannikmäe K, Samarasekera N, Martînez-Gonzâlez NA, et al. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:9649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarron MO, Nicoll JA, Ironside JW, et al. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. Stroke 1999; 30:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 1999; 58:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011; 10:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo D, Kaushal R, Chakraborty R, et al. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005; 36:1874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosand J. Epistasis is coming: are we ready? Stroke 2005; 36:1879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Shulman JM, Jagiella JM, et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012; 78:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samarasekera N, Smith C, Al-Shahi Salman R. The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2012; 83:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979; 54:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Finklestein SP, Schaefer PW. Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996; 46:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005; 58:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weller RO, Nicoll JA. Cerebral amyloid angiopathy: both viper and maggot in the brain. Ann Neurol 2005; 58:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samarasekera N, Rodrigues MA, Toh PS, Al-Shahi R. Imaging features of intracerebral hemorrhage with cerebral amyloid angiopathy: Systematic review and meta-analysis. PLoS One 2017; 12:e0180923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viguier A, Raposo N, Patsoura S, et al. Subarachnoid and Subdural Hemorrhages in Lobar Intracerebral Hemorrhage Associated With Cerebral Amyloid Angiopathy. Stroke 2019; 50:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 2018; 17:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itoh Y, Yamada M, Hayakawa M, et al. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993; 116:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasi M, Marini S, Morotti A, et al. Cerebellar Hematoma Location: Implications for the Underlying Microangiopathy. Stroke 2018; 49:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koemans EA, Voigt S, Rasing I, et al. Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy. Stroke 2022; 53:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Incontri D, Marchina S, Andreev A, et al. Etiology of Primary Cerebellar Intracerebral Hemorrhage Based on Topographic Localization. Stroke 2023; 54:3074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Perosa V, Frosch MP, et al. Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy. Brain 2020; 143:3343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf CJ, Perret GE, Torner JC. Bleeding from cerebral arteriovenous malformations as part of their natural history. J Neurosurg 1983; 58:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng AL, Batool S, McCreary CR, et al. Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds. Stroke 2013; 44:2782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol 2022; 21:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998; 51:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Charidimou A. Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria. Stroke 2018; 49:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 1986; 45:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natté R, Vinters HV, Maat-Schieman ML, et al. Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Stroke 1998; 29:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verbeek MM, Kremer BP, Rikkert MO, et al. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009; 66:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renard D, Castelnovo G, Wacongne A, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol 2012; 259:2429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly JV, Donnan GA, Villemagne VL, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurol ME, Becker JA, Fotiadis P, et al. Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study. Neurology 2016; 87:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012; 79:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 2010; 68:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izumihara A, Ishihara T, Iwamoto N, et al. Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy. Stroke 1999; 30:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke 2022; 53:e282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000; 55:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward R, Ponamgi S, DeSimone CV, et al. Utility of HAS-BLED and CHA2DS2-VASc Scores Among Patients With Atrial Fibrillation and Imaging Evidence of Cerebral Amyloid Angiopathy. Mayo Clin Proc 2020; 95:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet 2019; 393:2613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70:2964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biffi A, Battey TW, Ayres AM, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011; 77:1840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Shoamanesh A, Al-Shahi Salman R, et al. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: The need for a balanced approach. Int J Stroke 2018; 13:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019; 50:e344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology 1995; 45:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Turc G, Oppenheim C, et al. Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis. Stroke 2017; 48:2084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 2009; 119:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang X, Dong Y, Qi X, et al. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013; 44:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004; 35:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leker RR, Khoury ST, Rafaeli G, et al. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009; 40:2581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012; 43:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996; 27:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kase CS, Williams JP, Wyatt DA, Mohr JP. Lobar intracerebral hematomas: clinical and CT analysis of 22 cases. Neurology 1982; 32:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massaro AR, Sacco RL, Mohr JP, et al. Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology 1991; 41:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Boulouis G, Roongpiboonsopit D, et al. Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: Large prospective cohort and preliminary meta-analysis. Int J Stroke 2019; 14:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinho J, Araújo JM, Costa AS, et al. Intracerebral Hemorrhage Recurrence in Patients with and without Cerebral Amyloid Angiopathy. Cerebrovasc Dis Extra 2021; 11:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasi M, Charidimou A, Boulouis G, et al. Mixed-location cerebral hemorrhage/microbleeds: Underlying microangiopathy and recurrence risk. Neurology 2018; 90:e119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Eng JA, Ning M, et al. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004; 35:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Peeters AP, Jäger R, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology 2013; 81:1666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raposo N, Charidimou A, Roongpiboonsopit D, et al. Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: A prognostic marker. Neurology 2020; 94:e968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fandler-Höfler S, Gattringer T, Enzinger C, Werring DJ. Comparison of Boston Criteria v2.0/v1.5 for Cerebral Amyloid Angiopathy to Predict Recurrent Intracerebral Hemorrhage. Stroke 2023; 54:1901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li L, Luengo-Fernandez R, Zuurbier SM, et al. Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study. J Neurol Neurosurg Psychiatry 2020; 91:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulin S, Labreuche J, Bombois S, et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016; 15:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong L, Charidimou A, Pasi M, et al. Predictors for Late Post-Intracerebral Hemorrhage Dementia in Patients with Probable Cerebral Amyloid Angiopathy. J Alzheimers Dis 2019; 71:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeerakathil T, Wolf PA, Beiser A, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004; 35:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker DA, Broderick DF, Kotsenas AL, Rubino FA. Routine use of gradient-echo MRI to screen for cerebral amyloid angiopathy in elderly patients. AJR Am J Roentgenol 2004; 182:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry 2008; 79:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008; 70:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Nandigam RN, Delgado P, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke 2009; 40:2382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernooij MW, Haag MD, van der Lugt A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 2009; 66:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregoire SM, Jäger HR, Yousry TA, et al. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry 2010; 81:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JH, Seo SW, Kim C, et al. Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol 2013; 73:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasi M, Pongpitakmetha T, Charidimou A, et al. Cerebellar Microbleed Distribution Patterns and Cerebral Amyloid Angiopathy. Stroke 2019; 50:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Meng L, Wang Z. Combined Cerebral Microbleeds With Lacunar Infarctions in Familial Cerebral Cavernous Malformations. JAMA Neurol 2019; 76:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Husseinzadeh H, Chiasakul T, Gimotty PA, et al. Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B. Haemophilia 2018; 24:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braemswig TB, Villringer K, Turc G, et al. Predictors of new remote cerebral microbleeds after IV thrombolysis for ischemic stroke. Neurology 2019; 92:e630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noorbakhsh-Sabet N, Pulakanti VC, Zand R. Uncommon Causes of Cerebral Microbleeds. J Stroke Cerebrovasc Dis 2017; 26:2043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper N, Morrison MA, Vladescu C, et al. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. Blood 2020; 136:2875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graff-Radford J, Lesnick T, Rabinstein AA, et al. Cerebral Microbleeds: Relationship to Antithrombotic Medications. Stroke 2021; 52:2347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danve A, Grafe M, Deodhar A. Amyloid beta-related angiitis--a case report and comprehensive review of literature of 94 cases. Semin Arthritis Rheum 2014; 44:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murai R, Kaji S, Kitai T, et al. The Clinical Significance of Cerebral Microbleeds in Infective Endocarditis Patients. Semin Thorac Cardiovasc Surg 2019; 31:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparacia G, Cannella R, Lo Re V, et al. Assessment of cerebral microbleeds by susceptibility-weighted imaging at 3T in patients with end-stage organ failure. Radiol Med 2018; 123:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irimia A, Van Horn JD, Vespa PM. Cerebral microhemorrhages due to traumatic brain injury and their effects on the aging human brain. Neurobiol Aging 2018; 66:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Banahan C, Janus J, et al. Perioperative Cerebral Microbleeds After Adult Cardiac Surgery. Stroke 2019; 50:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poels MM, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011; 42:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010; 74:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Etten ES, Auriel E, Haley KE, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke 2014; 45:2280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altmann-Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011; 42:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linn J, Herms J, Dichgans M, et al. Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy. AJNR Am J Neuroradiol 2008; 29:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calviere L, Cuvinciuc V, Raposo N, et al. Acute Convexity Subarachnoid Hemorrhage Related to Cerebral Amyloid Angiopathy: Clinicoradiological Features and Outcome. J Stroke Cerebrovasc Dis 2016; 25:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Jäger RH, Fox Z, et al. Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology 2013; 81:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Boulouis G, Xiong L, et al. Cortical Superficial Siderosis Evolution. Stroke 2019; 50:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martí-Fàbregas J, Camps-Renom P, Best JG, et al. Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis. Neurology 2023; 100:e1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollenweber FA, Opherk C, Zedde M, et al. Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology 2019; 92:e792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra K, Theodorou A, Katsanos AH, et al. Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis. Stroke 2022; 53:1944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabaee Damavandi P, Storti B, Fabin N, et al. Epilepsy in cerebral amyloid angiopathy: an observational retrospective study of a large population. Epilepsia 2023; 64:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ter Telgte A, Scherlek AA, Reijmer YD, et al. Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy. Acta Neuropathol 2020; 139:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberly WT, Gilson A, Rost NS, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009; 72:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fotiadis P, Reijmer YD, Van Veluw SJ, et al. White matter atrophy in cerebral amyloid angiopathy. Neurology 2020; 95:e554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Boulouis G, Haley K, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. Neurology 2016; 86:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ii Y, Ishikawa H, Matsuyama H, et al. Hypertensive Arteriopathy and Cerebral Amyloid Angiopathy in Patients with Cognitive Decline and Mixed Cerebral Microbleeds. J Alzheimers Dis 2020; 78:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Meegahage R, Fox Z, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry 2013; 84:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HH, Pasi M, Tsai LK, et al. Centrum Semiovale Perivascular Space and Amyloid Deposition in Spontaneous Intracerebral Hemorrhage. Stroke 2021; 52:2356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. Neurology 2013; 80:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Vonsattel JP, Stakes JW, et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993; 43:2073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zerna C, Modi J, Bilston L, et al. Cerebral Microbleeds and Cortical Superficial Siderosis in Patients Presenting With Minor Cerebrovascular Events. Stroke 2016; 47:2236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A. Cerebral amyloid angiopathy-related transient focal neurological episodes (CAA-TFNEs): A well-defined clinical-radiological syndrome. J Neurol Sci 2019; 406:116496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charidimou A, Peeters A, Fox Z, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 2012; 43:2324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EE, Charidimou A, Ayata C, et al. Cerebral Amyloid Angiopathy-Related Transient Focal Neurologic Episodes. Neurology 2021; 97:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Caro JM, de Lorenzo Martínez de Ubago I, de Celis Ruiz E, et al. Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death: A Systematic Review and Meta-analysis. JAMA Neurol 2022; 79:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roch JA, Nighoghossian N, Hermier M, et al. Transient neurologic symptoms related to cerebral amyloid angiopathy: usefulness of T2*-weighted imaging. Cerebrovasc Dis 2005; 20:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004; 55:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountain NB, Eberhard DA. Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Neurology 1996; 46:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwab P, Lidov HG, Schwartz RB, Anderson RJ. Cerebral amyloid angiopathy associated with primary angiitis of the central nervous system: report of 2 cases and review of the literature. Arthritis Rheum 2003; 49:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SM, Rapalino O, Frosch MP. Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure. N Engl J Med 2010; 363:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung KK, Anderson NE, Hutchinson D, et al. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011; 82:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodorou A, Palaiodimou L, Malhotra K, et al. Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis. Stroke 2023; 54:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oide T, Tokuda T, Takei Y, et al. Serial CT and MRI findings in a patient with isolated angiitis of the central nervous system associated with cerebral amyloid angiopathy. Amyloid 2002; 9:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Coz P, Mikol J, Ferrand J, et al. Granulomatous angiitis and cerebral amyloid angiopathy presenting as a mass lesion. Neuropathol Appl Neurobiol 1991; 17:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wengert O, Harms L, Siebert E. Cerebral amyloid angiopathy-related inflammation: a treatable cause of rapidly-progressive dementia. J Neuropsychiatry Clin Neurosci 2012; 24:E1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auriel E, Charidimou A, Gurol ME, et al. Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol 2016; 73:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermann DM, Keyvani K, van de Nes J, et al. Brain-reactive β-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy. Neurology 2011; 77:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piazza F, Greenberg SM, Savoiardo M, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 2013; 73:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura A, Sakurai T, Yoshikura N, et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. J Neuroinflammation 2013; 10:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh U, Gupta R, Krakauer JW, et al. Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 2004; 62:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antolini L, DiFrancesco JC, Zedde M, et al. Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study. Neurology 2021; 97:e1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloppenborg RP, Richard E, Sprengers ME, et al. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation 2010; 7:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakaguchi H, Ueda A, Kosaka T, et al. Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J Neuroinflammation 2011; 8:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountain NB, Lopes MB. Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone. Neurology 1999; 52:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandybur TI, Balko G. Cerebral amyloid angiopathy with granulomatous angiitis ameliorated by steroid-cytoxan treatment. Clin Neuropharmacol 1992; 15:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regenhardt RW, Thon JM, Das AS, et al. Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol 2020; 77:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 2015; 85:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46:1592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009; 40:3455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poels MM, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology 2012; 78:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Norden AG, van den Berg HA, de Laat KF, et al. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke 2011; 42:3382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregoire SM, Scheffler G, Jäger HR, et al. Strictly lobar microbleeds are associated with executive impairment in patients with ischemic stroke or transient ischemic attack. Stroke 2013; 44:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregoire SM, Charidimou A, Gadapa N, et al. Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study. Brain 2011; 134:2376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Veluw SJ, Lauer A, Charidimou A, et al. Evolution of DWI lesions in cerebral amyloid angiopathy: Evidence for ischemia. Neurology 2017; 89:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong L, van Veluw SJ, Bounemia N, et al. Cerebral Cortical Microinfarcts on Magnetic Resonance Imaging and Their Association With Cognition in Cerebral Amyloid Angiopathy. Stroke 2018; 49:2330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soontornniyomkij V, Lynch MD, Mermash S, et al. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy. Brain Pathol 2010; 20:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauer A, van Veluw SJ, William CM, et al. Microbleeds on MRI are associated with microinfarcts on autopsy in cerebral amyloid angiopathy. Neurology 2016; 87:1488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985; 18:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith EE, Nandigam KR, Chen YW, et al. MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke 2010; 41:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurol ME, Viswanathan A, Gidicsin C, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 2013; 73:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCreary CR, Beaudin AE, Subotic A, et al. Cross-sectional and longitudinal differences in peak skeletonized white matter mean diffusivity in cerebral amyloid angiopathy. Neuroimage Clin 2020; 27:102280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raposo N, Zanon Zotin MC, Schoemaker D, et al. Peak Width of Skeletonized Mean Diffusivity as Neuroimaging Biomarker in Cerebral Amyloid Angiopathy. AJNR Am J Neuroradiol 2021; 42:875.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1128 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22190361" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cerebral amyloid angiopathy in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056963" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9227694" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29244218" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Person-specific contribution of neuropathologies to cognitive loss in old age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21387377" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cerebral amyloid angiopathy pathology and cognitive domains in older persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29614657" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37035916" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Iatrogenic Cerebral Amyloid Angiopathy Post Neurosurgery: Frequency, Clinical Profile, Radiological Features, and Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144113" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111471" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Alzheimer disease and cerebrovascular pathology: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26354483" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evidence for human transmission of amyloid-βpathology and cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35577510" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35770667" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Amyloid-β(Aβ)-Related Cerebral Amyloid Angiopathy Causing Lobar Hemorrhage Decades After Childhood Neurosurgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2760643" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8418549" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lobar hemorrhage in the elderly. The undiminishing importance of hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20044530" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26325559" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31827267" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16178030" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32337337" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hereditary cerebral amyloid angiopathy, Piedmont-type mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7839831" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27590282" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10800967" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Charge alterations of E22 enhance the pathogenic properties of the amyloid beta-protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11441013" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pathogenic effects of D23N Iowa mutant amyloid beta -protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12801742" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14985348" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9189032" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9566379" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7654074" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21061402" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Variants at APOE influence risk of deep and lobar intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715706" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Genetic associations with brain microbleeds: Systematic review and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23457231" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8415756" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7585009" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10648765" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10436115" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411341" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21741316" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16100021" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16120843" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Epistasis is coming: are we ready?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22262751" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Genetic variation at CR1 increases risk of cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056966" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The association between cerebral amyloid angiopathy and intracerebral haemorrhage: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/759733" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinicopathologic studies of primary cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649586" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16130107" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16130089" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cerebral amyloid angiopathy: both viper and maggot in the brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28700676" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Imaging features of intracerebral hemorrhage with cerebral amyloid angiopathy: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31136281" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Subarachnoid and Subdural Hemorrhages in Lobar Intracerebral Hemorrhage Associated With Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29331631" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8336159" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29183952" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cerebellar Hematoma Location: Implications for the Underlying Microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34538086" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37842779" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Etiology of Primary Cerebellar Intracerebral Hemorrhage Based on Topographic Localization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32935842" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6827317" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Bleeding from cerebral arteriovenous malformations as part of their natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20421578" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23920014" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35841910" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9748011" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11222803" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29335334" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Diagnosis of Cerebral Amyloid Angiopathy: Evolution of the Boston Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3941328" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Cerebral amyloid angiopathy: the vascular pathology and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1763890" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9707198" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Microvasculopathy is associated with the number of cerebrovascular lesions in hereditary cerebral hemorrhage with amyloidosis, Dutch type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19743453" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22576334" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17683091" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142615" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27605173" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786597" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20865701" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9880384" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35579034" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11061249" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7631356" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32829908" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Utility of HAS-BLED and CHA2DS2-VASc Scores Among Patients With Atrial Fibrillation and Imaging Evidence of Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733144" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31128924" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29103847" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22049204" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Warfarin-related intraventricular hemorrhage: imaging and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29125055" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: The need for a balanced approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31662037" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723950" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28720659" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364982" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23704101" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15087556" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16214597" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19407227" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22588266" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8711797" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6889699" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Lobar intracerebral hematomas: clinical and CT analysis of 22 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1745342" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30785378" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: Large prospective cohort and preliminary meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33503633" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Intracerebral Hemorrhage Recurrence in Patients with and without Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29247070" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Mixed-location cerebral hemorrhage/microbleeds: Underlying microangiopathy and recurrence risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15073385" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24107862" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32019785" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Convexity subarachnoid hemorrhage in lobar intracerebral hemorrhage: A prognostic marker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37264913" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Comparison of Boston Criteria v2.0/v1.5 for Cerebral Amyloid Angiopathy to Predict Recurrent Intracerebral Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32165376" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27133238" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31403947" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Predictors for Late Post-Intracerebral Hemorrhage Dementia in Patients with Probable Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155954" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150006" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Routine use of gradient-echo MRI to screen for cerebral amyloid angiopathy in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18270235" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378884" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19443797" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Microbleeds versus macrobleeds: evidence for distinct entities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364926" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20522874" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23495089" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31159702" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Cerebellar Microbleed Distribution Patterns and Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31305865" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Combined Cerebral Microbleeds With Lacunar Infarctions in Familial Cerebral Cavernous Malformations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29282815" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30674591" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Predictors of new remote cerebral microbleeds after IV thrombolysis for ischemic stroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28826581" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Uncommon Causes of Cerebral Microbleeds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32750707" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Identification of occult cerebral microbleeds in adults with immune thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33966498" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Cerebral Microbleeds: Relationship to Antithrombotic Medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24636849" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Amyloid beta-related angiitis--a case report and comprehensive review of literature of 94 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287247" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The Clinical Significance of Cerebral Microbleeds in Infective Endocarditis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29455423" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Assessment of cerebral microbleeds by susceptibility-weighted imaging at 3T in patients with end-stage organ failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29579686" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Cerebral microhemorrhages due to traumatic brain injury and their effects on the aging human brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30572811" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Perioperative Cerebral Microbleeds After Adult Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21307170" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20548041" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24947286" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Incidence of symptomatic hemorrhage in patients with lobar microbleeds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233474" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Cerebral microbleeds are predictive of mortality in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17947366" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26923093" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Acute Convexity Subarachnoid Hemorrhage Related to Cerebral Amyloid Angiopathy: Clinicoradiological Features and Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23864315" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30869563" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Cortical Superficial Siderosis Evolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36535778" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30674596" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Prognostic relevance of cortical superficial siderosis in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35264008" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36515439" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Epilepsy in cerebral amyloid angiopathy: an observational retrospective study of a large population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32108259" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19349602" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32611644" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : White matter atrophy in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26747886" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33185609" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Hypertensive Arteriopathy and Cerebral Amyloid Angiopathy in Patients with Cognitive Decline and Mixed Cerebral Microbleeds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23412074" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33874751" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Centrum Semiovale Perivascular Space and Amyloid Deposition in Spontaneous Intracerebral Hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23553482" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Topography of dilated perivascular spaces in subjects from a memory clinic cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413970" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27507863" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Cerebral Microbleeds and Cortical Superficial Siderosis in Patients Presenting With Minor Cerebrovascular Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31703811" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Cerebral amyloid angiopathy-related transient focal neurological episodes (CAA-TFNEs): A well-defined clinical-radiological syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22798323" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34016709" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Cerebral Amyloid Angiopathy-Related Transient Focal Neurologic Episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34779831" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16210853" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Transient neurologic symptoms related to cerebral amyloid angiopathy: usefulness of T2*-weighted imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14755729" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Clinical manifestations of cerebral amyloid angiopathy-related inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452586" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Course of cerebral amyloid angiopathy-related inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8559373" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659428" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12794799" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Cerebral amyloid angiopathy associated with primary angiitis of the central nervous system: report of 2 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660406" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20935328" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Cerebral amyloid angiopathy related inflammation: three case reports and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36453271" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Clinical, Neuroimaging, and Genetic Markers in Cerebral Amyloid Angiopathy-Related Inflammation: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12557755" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Serial CT and MRI findings in a patient with isolated angiitis of the central nervous system associated with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1713309" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Granulomatous angiitis and cerebral amyloid angiopathy presenting as a mass lesion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22450625" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Cerebral amyloid angiopathy-related inflammation: a treatable cause of rapidly-progressive dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26720093" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775736" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Brain-reactiveβ-amyloid antibodies in primary CNS angiitis with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23625526" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Anti-amyloidβautoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23497126" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14872042" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Reversible leukoencephalopathy associated with cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34531298" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20214781" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21914214" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10025812" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1394245" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Cerebral amyloid angiopathy with granulomatous angiitis ameliorated by steroid-cytoxan treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32568365" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy-Related Inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26537052" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649554" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12058090" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19762705" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22262748" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940975" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23482601" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Strictly lobar microbleeds are associated with executive impairment in patients with ischemic stroke or transient ischemic attack.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841203" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29070668" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Evolution of DWI lesions in cerebral amyloid angiopathy: Evidence for ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30355109" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Cerebral Cortical Microinfarcts on Magnetic Resonance Imaging and Their Association With Cognition in Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19725828" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27613583" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Microbleeds on MRI are associated with microinfarcts on autopsy in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4037751" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20689084" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23424091" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32521475" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Cross-sectional and longitudinal differences in peak skeletonized white matter mean diffusivity in cerebral amyloid angiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33664113" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Peak Width of Skeletonized Mean Diffusivity as Neuroimaging Biomarker in Cerebral Amyloid Angiopathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
